Go to the briefing

Get a name you can check

Which substance are we talking about?

If an offer uses the word peptide, ask which one. The name describes a substance with tiny chemical parts forming a short chain. Think of beads threaded together; insulin is a familiar member of this group. The word alone does not identify the medicine being offered.

Begin · a learning step

Keep drug names separate from repair claims

In FDA records checked in September 2026, BPC-157 had no approved drug product in the United States.

Note A

FDA is short for Food and Drug Administration, the federal drug-review agency.

Ask for the full product name and how it would be given. Write both down. Ask the clinician to explain what the proposal is meant to do for your problem.

Another name that needs care

Thymosin beta-4 is the name of a larger peptide. TB-500 names a small piece of it. The two names do not describe the same whole substance.

An FDA letter reviewed in September 2026 named products sold as TB-500 as unapproved drugs.

Note B

The letter states FDA’s claims about a particular seller. It is not a court decision.

Ask whether the full name on the proposed label matches the name used in the evidence. Do not let similar names stand in for the same product.

Keep the name through each question

Carry the exact name into the discussion of evidence, pharmacy checks and cost. Add the form: for example, something applied to skin or something injected.

Ask about the form being proposed, rather than treating all forms as alike.

Ask what the evidence shows Understand made-to-order medicines

Page notes

  1. FDA application records

    Checking approval tells you whether an approved drug exists. Ask which ingredient rule permits pharmacy preparation to order before assuming that route is allowed. The made-to-order briefing explains those rules.

    Back to the briefing
  2. FDA letter naming the products

    The letter states FDA’s claims about particular products. A court has not decided those claims in this letter.

    Back to the briefing